Loading stock…

Legend Biotech Corporation (LEGN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Legend Biotech Corporation

LEGNMarket cap $3.70BPrice $19.1

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops cell therapies that reprogram the body's own immune system to hunt down cancer. Its CAR-T treatment Carvykti, co-developed with Johnson & Johnson, is already reshaping how doctors fight multiple myeloma.

In Bastion Portfolios?

52W Return-40%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+106%10

Revenue Forecast

Rev CAGR (1y)+39%9

Rev CAGR (3y)+26%9

Rev CAGR (5y)+20%9

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+20%5

EPS Growth Y+3+34%9

Quality

Margins

EBIT Margin-4%1

Net Income Margin-7%1

Free Cash Flow Margin-10%2

Debt

Net Debt/EBITDAna–

Efficiency

ROE-8%1

ROA-5%1

Earnings Stabilityna–

GEAR+WEAK16

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)272

P/E Ratio (Forward 3y)107

P/BV3.05

EV Multiples

EV/EBITDA Fwd551

EV/EBIT Fwd3081

Yield

Free Cash Flow Yield-3.3%2

Dividend Yieldna–

Momentum

Short term

1 month return-7%4

3 month return-31%1

YTD return-12%3

Mid term

Price vs 52wHigh51%1

1 year return-41%1

Long term

3 year return-72%1

5 year return-64%1

Risk Shield

Price Risk

Beta0.67

Volatility71%1

Free Cash Flow

Free Cash Flow Margin-10%2

Free Cash Flow Yield-3.3%2

Quality

ROCE-4%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

LEGNLegend Biotech

Revenue FY25$1.0B

GROWTH RATING↗

VERY STRONG87 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+106%10

Revenue, next 1Y+39%9

Revenue, next 3Y, CAGR+26%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+34%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 87% of companies worldwide.

Revenue grew 106%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 26%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 106%/yr over the last 3 years; forecasts see it cooling to 26%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-31%1

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-41%1

3-year return-72%1

5-year return-64%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-72% over three years and -64% over five), behind 90% of the market.

It's down 41% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-31%) and so far this year (-12%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Legend Biotech. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

LEGNLegend Biotech

Revenue FY25$1.0B

GROWTH RATING↗

VERY STRONG87 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+106%10

Revenue, next 1Y+39%9

Revenue, next 3Y, CAGR+26%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+34%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 87% of companies worldwide.

Revenue grew 106%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 26%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 106%/yr over the last 3 years; forecasts see it cooling to 26%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-31%1

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-41%1

3-year return-72%1

5-year return-64%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-72% over three years and -64% over five), behind 90% of the market.

It's down 41% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-31%) and so far this year (-12%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Legend Biotech. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community